Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension research Vol. 43; no. 10; pp. 1028 - 1046
Main Authors: Shibata, Shigeru, Arima, Hisatomi, Asayama, Kei, Hoshide, Satoshi, Ichihara, Atsuhiro, Ishimitsu, Toshihiko, Kario, Kazuomi, Kishi, Takuya, Mogi, Masaki, Nishiyama, Akira, Ohishi, Mitsuru, Ohkubo, Takayoshi, Tamura, Kouichi, Tanaka, Masami, Yamamoto, Eiichiro, Yamamoto, Koichi, Itoh, Hiroshi
Format: Journal Article
Language:English
Published: England Nature Publishing Group 01.10.2020
Subjects:
Angiotensin-Converting Enzyme 2
Antihypertensive Agents - therapeutic use
Betacoronavirus - metabolism
Cerebrovascular Disorders - virology
Coronavirus Infections - complications
Coronavirus Infections - mortality
Coronaviruses
COVID-19
Diuretics
Host-Pathogen Interactions
Humans
Hypertension
Hypertension - complications
Hypertension - drug therapy
Hypertension - epidemiology
Pandemics
Peptidyl-Dipeptidase A - metabolism
Pneumonia, Viral - complications
Pneumonia, Viral - mortality
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
cardiovascular disease
severe acute respiratory syndrome coronavirus 2
angiotensin converting enzyme 2
hypertension
ISSN:0916-9636, 1348-4214, 1348-4214
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a "New Normal" lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0916-9636
1348-4214
1348-4214
DOI:10.1038/s41440-020-0515-0